 | Up a level |
Journal Article
Ahmadzadehfar, H., Albers, P., Bockisch, A., Boegemann, M., Boehme, C., Burchert, W., Dietlein, M., Drzezga, A., Fabry, U., Feldmann, G., Heidenreich, A., Heinzel, A., Herrmann, K., Heyll, A., Hoehling, C., Kreuzer, C., Laufer, D., Mengel, R., Mottaghy, F. M., Mueller, H-W., Mueller, S. C., Ost, E., Rahbar, K., Reifenhaeuser, W., Schaefers, M., Schlenkhoff, C., Schmidt, M., Schmidt-Wolf, I., Wildenhain, C., Zimmer, B. and Essler, M. (2018). Lutetium-177-PSMA radioligand therapy. Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Dusseldorf, Essen, and Cologne and the MDK Nordrhein. Urologe, 57 (6). S. 709 - 714. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Gschwend, J. E., Albers, P., Boegemann, M., Goebell, P., Heidenreich, A., Klier, J., Koenig, F., Machtens, S., Pantel, K. and Thomas, C. (2018). Metastatic castration-resistant prostate cancer. Use of cabazitaxel taking into consideration current data. Urologe, 57 (1). S. 34 - 40. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563
Miller, K., Albers, P., Eichenauer, R., Geiges, G., Grimm, M-O., Koenig, F., Mickisch, G., Pfister, D., Schwentner, C., Suttmann, H. and Zastrow, S. (2016). Metastatic castration-resistant prostate cancer. Clinical data, new treatment options and therapy monitoring. Urologe, 55 (9). S. 1206 - 1213. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0563